nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—CYP1A1—polycystic ovary syndrome	0.485	1	CbGaD
Gefitinib—SBK1—endometrium—polycystic ovary syndrome	0.00481	0.0253	CbGeAlD
Gefitinib—SBK1—pituitary gland—polycystic ovary syndrome	0.00435	0.0229	CbGeAlD
Gefitinib—CYP2C19—urine—polycystic ovary syndrome	0.00429	0.0226	CbGeAlD
Gefitinib—Erlotinib—LTK—polycystic ovary syndrome	0.00414	0.324	CrCbGaD
Gefitinib—CHEK2—pituitary gland—polycystic ovary syndrome	0.00379	0.02	CbGeAlD
Gefitinib—CHEK2—adipose tissue—polycystic ovary syndrome	0.00378	0.0199	CbGeAlD
Gefitinib—ERBB3—embryo—polycystic ovary syndrome	0.0035	0.0185	CbGeAlD
Gefitinib—CHEK2—adrenal gland—polycystic ovary syndrome	0.00339	0.0178	CbGeAlD
Gefitinib—HIPK4—endocrine gland—polycystic ovary syndrome	0.00333	0.0176	CbGeAlD
Gefitinib—CYP2C9—urine—polycystic ovary syndrome	0.00333	0.0175	CbGeAlD
Gefitinib—Vandetanib—FLT4—polycystic ovary syndrome	0.00329	0.258	CrCbGaD
Gefitinib—CHEK2—female gonad—polycystic ovary syndrome	0.00316	0.0166	CbGeAlD
Gefitinib—CHEK2—vagina—polycystic ovary syndrome	0.00314	0.0165	CbGeAlD
Gefitinib—Appetite absent—Metformin—polycystic ovary syndrome	0.00298	0.118	CcSEcCtD
Gefitinib—CSNK1E—adrenal cortex—polycystic ovary syndrome	0.00297	0.0157	CbGeAlD
Gefitinib—IRAK4—adrenal cortex—polycystic ovary syndrome	0.00293	0.0154	CbGeAlD
Gefitinib—Vandetanib—LTK—polycystic ovary syndrome	0.00273	0.213	CrCbGaD
Gefitinib—MKNK2—adrenal cortex—polycystic ovary syndrome	0.00273	0.0144	CbGeAlD
Gefitinib—MKNK1—adrenal cortex—polycystic ovary syndrome	0.0027	0.0142	CbGeAlD
Gefitinib—CSNK1E—endometrium—polycystic ovary syndrome	0.00266	0.014	CbGeAlD
Gefitinib—EPHA6—endocrine gland—polycystic ovary syndrome	0.00263	0.0139	CbGeAlD
Gefitinib—IRAK4—endometrium—polycystic ovary syndrome	0.00262	0.0138	CbGeAlD
Gefitinib—EGFR—uterus—polycystic ovary syndrome	0.00255	0.0134	CbGeAlD
Gefitinib—CYP3A4—urine—polycystic ovary syndrome	0.00254	0.0134	CbGeAlD
Gefitinib—CYP2D6—urine—polycystic ovary syndrome	0.0025	0.0131	CbGeAlD
Gefitinib—EGFR—adipose tissue—polycystic ovary syndrome	0.00249	0.0131	CbGeAlD
Gefitinib—CSNK1E—uterus—polycystic ovary syndrome	0.00245	0.0129	CbGeAlD
Gefitinib—MKNK2—endometrium—polycystic ovary syndrome	0.00244	0.0128	CbGeAlD
Gefitinib—MKNK1—endometrium—polycystic ovary syndrome	0.00241	0.0127	CbGeAlD
Gefitinib—CSNK1E—pituitary gland—polycystic ovary syndrome	0.0024	0.0127	CbGeAlD
Gefitinib—CSNK1E—adipose tissue—polycystic ovary syndrome	0.00239	0.0126	CbGeAlD
Gefitinib—IRAK4—pituitary gland—polycystic ovary syndrome	0.00237	0.0125	CbGeAlD
Gefitinib—ERBB3—uterus—polycystic ovary syndrome	0.00236	0.0124	CbGeAlD
Gefitinib—IRAK4—adipose tissue—polycystic ovary syndrome	0.00236	0.0124	CbGeAlD
Gefitinib—ERBB3—adipose tissue—polycystic ovary syndrome	0.00231	0.0122	CbGeAlD
Gefitinib—Nail disorder—Metformin—polycystic ovary syndrome	0.00229	0.0907	CcSEcCtD
Gefitinib—MKNK2—uterus—polycystic ovary syndrome	0.00225	0.0118	CbGeAlD
Gefitinib—EGFR—adrenal gland—polycystic ovary syndrome	0.00223	0.0118	CbGeAlD
Gefitinib—MKNK2—pituitary gland—polycystic ovary syndrome	0.00221	0.0116	CbGeAlD
Gefitinib—MKNK2—adipose tissue—polycystic ovary syndrome	0.0022	0.0116	CbGeAlD
Gefitinib—IRAK1—adipose tissue—polycystic ovary syndrome	0.0022	0.0116	CbGeAlD
Gefitinib—MKNK1—pituitary gland—polycystic ovary syndrome	0.00218	0.0115	CbGeAlD
Gefitinib—MKNK1—adipose tissue—polycystic ovary syndrome	0.00217	0.0114	CbGeAlD
Gefitinib—CSNK1E—adrenal gland—polycystic ovary syndrome	0.00215	0.0113	CbGeAlD
Gefitinib—IRAK4—adrenal gland—polycystic ovary syndrome	0.00211	0.0111	CbGeAlD
Gefitinib—EGFR—female gonad—polycystic ovary syndrome	0.00208	0.011	CbGeAlD
Gefitinib—CSNK1E—female gonad—polycystic ovary syndrome	0.002	0.0105	CbGeAlD
Gefitinib—CSNK1E—vagina—polycystic ovary syndrome	0.00199	0.0105	CbGeAlD
Gefitinib—MAP2K5—adrenal cortex—polycystic ovary syndrome	0.00198	0.0104	CbGeAlD
Gefitinib—IRAK4—female gonad—polycystic ovary syndrome	0.00197	0.0104	CbGeAlD
Gefitinib—MKNK2—adrenal gland—polycystic ovary syndrome	0.00197	0.0104	CbGeAlD
Gefitinib—IRAK1—adrenal gland—polycystic ovary syndrome	0.00197	0.0104	CbGeAlD
Gefitinib—IRAK4—vagina—polycystic ovary syndrome	0.00196	0.0103	CbGeAlD
Gefitinib—MKNK1—adrenal gland—polycystic ovary syndrome	0.00195	0.0102	CbGeAlD
Gefitinib—ERBB3—female gonad—polycystic ovary syndrome	0.00193	0.0102	CbGeAlD
Gefitinib—CSNK1E—endocrine gland—polycystic ovary syndrome	0.00186	0.00981	CbGeAlD
Gefitinib—MKNK2—female gonad—polycystic ovary syndrome	0.00184	0.00968	CbGeAlD
Gefitinib—IRAK1—female gonad—polycystic ovary syndrome	0.00184	0.00968	CbGeAlD
Gefitinib—STK10—uterus—polycystic ovary syndrome	0.00183	0.00962	CbGeAlD
Gefitinib—MKNK2—vagina—polycystic ovary syndrome	0.00183	0.00962	CbGeAlD
Gefitinib—MKNK1—female gonad—polycystic ovary syndrome	0.00181	0.00956	CbGeAlD
Gefitinib—MKNK1—vagina—polycystic ovary syndrome	0.0018	0.0095	CbGeAlD
Gefitinib—ERBB3—endocrine gland—polycystic ovary syndrome	0.0018	0.00947	CbGeAlD
Gefitinib—STK10—adipose tissue—polycystic ovary syndrome	0.00179	0.00941	CbGeAlD
Gefitinib—MAP2K5—endometrium—polycystic ovary syndrome	0.00177	0.00932	CbGeAlD
Gefitinib—MKNK2—endocrine gland—polycystic ovary syndrome	0.00171	0.009	CbGeAlD
Gefitinib—MKNK1—endocrine gland—polycystic ovary syndrome	0.00169	0.00889	CbGeAlD
Gefitinib—STK10—adrenal gland—polycystic ovary syndrome	0.0016	0.00844	CbGeAlD
Gefitinib—MAP2K5—pituitary gland—polycystic ovary syndrome	0.0016	0.00844	CbGeAlD
Gefitinib—MAP2K5—adipose tissue—polycystic ovary syndrome	0.0016	0.0084	CbGeAlD
Gefitinib—STK10—female gonad—polycystic ovary syndrome	0.00149	0.00787	CbGeAlD
Gefitinib—STK10—vagina—polycystic ovary syndrome	0.00148	0.00782	CbGeAlD
Gefitinib—ORM1—endometrium—polycystic ovary syndrome	0.00144	0.00757	CbGeAlD
Gefitinib—MAP2K5—adrenal gland—polycystic ovary syndrome	0.00143	0.00754	CbGeAlD
Gefitinib—STK10—endocrine gland—polycystic ovary syndrome	0.00139	0.00732	CbGeAlD
Gefitinib—MAP2K5—female gonad—polycystic ovary syndrome	0.00133	0.00703	CbGeAlD
Gefitinib—MAP2K5—vagina—polycystic ovary syndrome	0.00133	0.00699	CbGeAlD
Gefitinib—MAP2K5—endocrine gland—polycystic ovary syndrome	0.00124	0.00654	CbGeAlD
Gefitinib—Iloperidone—ADRA1A—polycystic ovary syndrome	0.0011	0.0858	CrCbGaD
Gefitinib—ALB—adrenal gland—polycystic ovary syndrome	0.00102	0.00537	CbGeAlD
Gefitinib—ORM1—endocrine gland—polycystic ovary syndrome	0.00101	0.00531	CbGeAlD
Gefitinib—Dehydration—Metformin—polycystic ovary syndrome	0.001	0.0397	CcSEcCtD
Gefitinib—ABCG2—adrenal cortex—polycystic ovary syndrome	0.000964	0.00508	CbGeAlD
Gefitinib—Pancreatitis—Metformin—polycystic ovary syndrome	0.000913	0.0362	CcSEcCtD
Gefitinib—Vandetanib—VEGFA—polycystic ovary syndrome	0.000879	0.0687	CrCbGaD
Gefitinib—ABCG2—endometrium—polycystic ovary syndrome	0.000861	0.00454	CbGeAlD
Gefitinib—Infestation—Metformin—polycystic ovary syndrome	0.000831	0.0329	CcSEcCtD
Gefitinib—Infestation NOS—Metformin—polycystic ovary syndrome	0.000831	0.0329	CcSEcCtD
Gefitinib—ABCG2—uterus—polycystic ovary syndrome	0.000793	0.00418	CbGeAlD
Gefitinib—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.000785	0.0311	CcSEcCtD
Gefitinib—ABCG2—pituitary gland—polycystic ovary syndrome	0.000779	0.0041	CbGeAlD
Gefitinib—ABCG2—adipose tissue—polycystic ovary syndrome	0.000776	0.00409	CbGeAlD
Gefitinib—CYP2C19—vagina—polycystic ovary syndrome	0.00076	0.004	CbGeAlD
Gefitinib—CYP1A1—uterus—polycystic ovary syndrome	0.000753	0.00397	CbGeAlD
Gefitinib—Hepatitis—Metformin—polycystic ovary syndrome	0.000746	0.0295	CcSEcCtD
Gefitinib—CYP1A1—adipose tissue—polycystic ovary syndrome	0.000737	0.00388	CbGeAlD
Gefitinib—Oedema peripheral—Metformin—polycystic ovary syndrome	0.000734	0.0291	CcSEcCtD
Gefitinib—CYP3A5—adipose tissue—polycystic ovary syndrome	0.00072	0.00379	CbGeAlD
Gefitinib—CYP2C19—endocrine gland—polycystic ovary syndrome	0.000711	0.00375	CbGeAlD
Gefitinib—Eye disorder—Metformin—polycystic ovary syndrome	0.000697	0.0276	CcSEcCtD
Gefitinib—ABCG2—adrenal gland—polycystic ovary syndrome	0.000696	0.00367	CbGeAlD
Gefitinib—Cardiac disorder—Metformin—polycystic ovary syndrome	0.000692	0.0274	CcSEcCtD
Gefitinib—Angiopathy—Metformin—polycystic ovary syndrome	0.000676	0.0268	CcSEcCtD
Gefitinib—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.000672	0.0266	CcSEcCtD
Gefitinib—Malnutrition—Metformin—polycystic ovary syndrome	0.000649	0.0257	CcSEcCtD
Gefitinib—ABCG2—female gonad—polycystic ovary syndrome	0.000649	0.00342	CbGeAlD
Gefitinib—ABCG2—vagina—polycystic ovary syndrome	0.000645	0.0034	CbGeAlD
Gefitinib—Erlotinib—CYP1A1—polycystic ovary syndrome	0.000644	0.0503	CrCbGaD
Gefitinib—CYP1A1—female gonad—polycystic ovary syndrome	0.000616	0.00325	CbGeAlD
Gefitinib—CYP1A1—vagina—polycystic ovary syndrome	0.000612	0.00323	CbGeAlD
Gefitinib—CYP3A5—female gonad—polycystic ovary syndrome	0.000602	0.00317	CbGeAlD
Gefitinib—CYP3A5—vagina—polycystic ovary syndrome	0.000599	0.00315	CbGeAlD
Gefitinib—Malaise—Metformin—polycystic ovary syndrome	0.000585	0.0232	CcSEcCtD
Gefitinib—ABCB1—embryo—polycystic ovary syndrome	0.00058	0.00306	CbGeAlD
Gefitinib—CYP1A1—endocrine gland—polycystic ovary syndrome	0.000573	0.00302	CbGeAlD
Gefitinib—CYP3A5—endocrine gland—polycystic ovary syndrome	0.00056	0.00295	CbGeAlD
Gefitinib—CYP2C9—endocrine gland—polycystic ovary syndrome	0.000551	0.0029	CbGeAlD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.000549	0.0217	CcSEcCtD
Gefitinib—Infection—Metformin—polycystic ovary syndrome	0.000526	0.0208	CcSEcCtD
Gefitinib—Shock—Metformin—polycystic ovary syndrome	0.000521	0.0206	CcSEcCtD
Gefitinib—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000519	0.0206	CcSEcCtD
Gefitinib—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.000519	0.0205	CcSEcCtD
Gefitinib—Skin disorder—Metformin—polycystic ovary syndrome	0.000515	0.0204	CcSEcCtD
Gefitinib—Anorexia—Metformin—polycystic ovary syndrome	0.000505	0.02	CcSEcCtD
Gefitinib—Hypotension—Metformin—polycystic ovary syndrome	0.000495	0.0196	CcSEcCtD
Gefitinib—ABCB1—adrenal cortex—polycystic ovary syndrome	0.000475	0.0025	CbGeAlD
Gefitinib—Dyspnoea—Metformin—polycystic ovary syndrome	0.000472	0.0187	CcSEcCtD
Gefitinib—Decreased appetite—Metformin—polycystic ovary syndrome	0.00046	0.0182	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000457	0.0181	CcSEcCtD
Gefitinib—Fatigue—Metformin—polycystic ovary syndrome	0.000457	0.0181	CcSEcCtD
Gefitinib—Constipation—Metformin—polycystic ovary syndrome	0.000453	0.0179	CcSEcCtD
Gefitinib—CYP2D6—female gonad—polycystic ovary syndrome	0.000445	0.00234	CbGeAlD
Gefitinib—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000433	0.0172	CcSEcCtD
Gefitinib—ABCB1—endometrium—polycystic ovary syndrome	0.000425	0.00224	CbGeAlD
Gefitinib—Urticaria—Metformin—polycystic ovary syndrome	0.000421	0.0167	CcSEcCtD
Gefitinib—CYP3A4—endocrine gland—polycystic ovary syndrome	0.00042	0.00221	CbGeAlD
Gefitinib—Abdominal pain—Metformin—polycystic ovary syndrome	0.000419	0.0166	CcSEcCtD
Gefitinib—CYP2D6—endocrine gland—polycystic ovary syndrome	0.000414	0.00218	CbGeAlD
Gefitinib—ABCB1—uterus—polycystic ovary syndrome	0.000391	0.00206	CbGeAlD
Gefitinib—ABCB1—pituitary gland—polycystic ovary syndrome	0.000384	0.00202	CbGeAlD
Gefitinib—ABCB1—adipose tissue—polycystic ovary syndrome	0.000383	0.00202	CbGeAlD
Gefitinib—Asthenia—Metformin—polycystic ovary syndrome	0.00038	0.0151	CcSEcCtD
Gefitinib—Pruritus—Metformin—polycystic ovary syndrome	0.000375	0.0148	CcSEcCtD
Gefitinib—Diarrhoea—Metformin—polycystic ovary syndrome	0.000362	0.0144	CcSEcCtD
Gefitinib—ABCB1—adrenal gland—polycystic ovary syndrome	0.000343	0.00181	CbGeAlD
Gefitinib—Vomiting—Metformin—polycystic ovary syndrome	0.000337	0.0133	CcSEcCtD
Gefitinib—Rash—Metformin—polycystic ovary syndrome	0.000334	0.0132	CcSEcCtD
Gefitinib—Dermatitis—Metformin—polycystic ovary syndrome	0.000334	0.0132	CcSEcCtD
Gefitinib—ABCB1—female gonad—polycystic ovary syndrome	0.00032	0.00169	CbGeAlD
Gefitinib—ABCB1—vagina—polycystic ovary syndrome	0.000318	0.00168	CbGeAlD
Gefitinib—Nausea—Metformin—polycystic ovary syndrome	0.000315	0.0125	CcSEcCtD
Gefitinib—ABCB1—endocrine gland—polycystic ovary syndrome	0.000298	0.00157	CbGeAlD
Gefitinib—MKNK1—Disease—IL6—polycystic ovary syndrome	1.58e-05	5.48e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—RRM2—polycystic ovary syndrome	1.57e-05	5.45e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IRS1—polycystic ovary syndrome	1.56e-05	5.44e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—POMC—polycystic ovary syndrome	1.56e-05	5.43e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	1.56e-05	5.43e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—CYP19A1—polycystic ovary syndrome	1.56e-05	5.42e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AKR1C2—polycystic ovary syndrome	1.56e-05	5.41e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—TEAD2—polycystic ovary syndrome	1.56e-05	5.41e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—INS—polycystic ovary syndrome	1.55e-05	5.4e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—ATF1—polycystic ovary syndrome	1.55e-05	5.38e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IRS2—polycystic ovary syndrome	1.54e-05	5.36e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CRP—polycystic ovary syndrome	1.54e-05	5.36e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—NAMPT—polycystic ovary syndrome	1.54e-05	5.34e-05	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—IL6—polycystic ovary syndrome	1.54e-05	5.34e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—HSD3B1—polycystic ovary syndrome	1.53e-05	5.33e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—LHB—polycystic ovary syndrome	1.52e-05	5.28e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—HSD3B1—polycystic ovary syndrome	1.52e-05	5.28e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CYP11A1—polycystic ovary syndrome	1.52e-05	5.27e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—YAP1—polycystic ovary syndrome	1.51e-05	5.25e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.51e-05	5.25e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—POMC—polycystic ovary syndrome	1.51e-05	5.24e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IGF1—polycystic ovary syndrome	1.5e-05	5.23e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	1.5e-05	5.22e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—AKT2—polycystic ovary syndrome	1.5e-05	5.22e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—INS—polycystic ovary syndrome	1.5e-05	5.21e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—MTHFR—polycystic ovary syndrome	1.5e-05	5.2e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IRS2—polycystic ovary syndrome	1.49e-05	5.19e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—HSD3B2—polycystic ovary syndrome	1.49e-05	5.16e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—LHB—polycystic ovary syndrome	1.48e-05	5.16e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—SULT2A1—polycystic ovary syndrome	1.47e-05	5.13e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—LEP—polycystic ovary syndrome	1.46e-05	5.07e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—NAMPT—polycystic ovary syndrome	1.45e-05	5.04e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—HSD3B2—polycystic ovary syndrome	1.45e-05	5.04e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IGF1—polycystic ovary syndrome	1.45e-05	5.04e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—AKT2—polycystic ovary syndrome	1.45e-05	5.03e-05	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—IL6—polycystic ovary syndrome	1.45e-05	5.03e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.44e-05	5.02e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—AKR1C1—polycystic ovary syndrome	1.44e-05	5e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CYP11A1—polycystic ovary syndrome	1.43e-05	4.98e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—AKR1C3—polycystic ovary syndrome	1.43e-05	4.98e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—RRM2—polycystic ovary syndrome	1.43e-05	4.97e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NGFR—polycystic ovary syndrome	1.43e-05	4.97e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.43e-05	4.96e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—IRS2—polycystic ovary syndrome	1.42e-05	4.95e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	1.42e-05	4.95e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.42e-05	4.95e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—POMC—polycystic ovary syndrome	1.42e-05	4.93e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PRL—polycystic ovary syndrome	1.42e-05	4.92e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CYP17A1—polycystic ovary syndrome	1.41e-05	4.9e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—AKR1C1—polycystic ovary syndrome	1.4e-05	4.88e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—LHB—polycystic ovary syndrome	1.4e-05	4.86e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—GNAS—polycystic ovary syndrome	1.39e-05	4.83e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—LHB—polycystic ovary syndrome	1.39e-05	4.82e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—YAP1—polycystic ovary syndrome	1.38e-05	4.79e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.38e-05	4.78e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—IGF1—polycystic ovary syndrome	1.37e-05	4.76e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—AKT2—polycystic ovary syndrome	1.37e-05	4.76e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—HSD3B2—polycystic ovary syndrome	1.37e-05	4.75e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.36e-05	4.74e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—HSD3B2—polycystic ovary syndrome	1.35e-05	4.71e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—AKR1C3—polycystic ovary syndrome	1.35e-05	4.71e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IRS1—polycystic ovary syndrome	1.35e-05	4.68e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.34e-05	4.67e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CYP17A1—polycystic ovary syndrome	1.33e-05	4.63e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—NCOR1—polycystic ovary syndrome	1.32e-05	4.6e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—SULT2A1—polycystic ovary syndrome	1.32e-05	4.6e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—AKR1C1—polycystic ovary syndrome	1.32e-05	4.6e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—NAMPT—polycystic ovary syndrome	1.32e-05	4.6e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.32e-05	4.57e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—AKR1C1—polycystic ovary syndrome	1.31e-05	4.56e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CYP11A1—polycystic ovary syndrome	1.31e-05	4.54e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	1.3e-05	4.53e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IRS1—polycystic ovary syndrome	1.3e-05	4.53e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—SERPINE1—polycystic ovary syndrome	1.3e-05	4.52e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.3e-05	4.51e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—SULT2A1—polycystic ovary syndrome	1.29e-05	4.49e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—RRM2—polycystic ovary syndrome	1.28e-05	4.46e-05	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—IL6—polycystic ovary syndrome	1.27e-05	4.41e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—CYP1A1—polycystic ovary syndrome	1.26e-05	4.36e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—POMC—polycystic ovary syndrome	1.25e-05	4.36e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—RRM2—polycystic ovary syndrome	1.25e-05	4.35e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—INS—polycystic ovary syndrome	1.25e-05	4.34e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—AKT2—polycystic ovary syndrome	1.25e-05	4.33e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—GNAS—polycystic ovary syndrome	1.25e-05	4.33e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—IRS1—polycystic ovary syndrome	1.24e-05	4.32e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.24e-05	4.32e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—YAP1—polycystic ovary syndrome	1.24e-05	4.3e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	1.24e-05	4.3e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—AKR1C3—polycystic ovary syndrome	1.23e-05	4.29e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—IL6—polycystic ovary syndrome	1.23e-05	4.26e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—TH—polycystic ovary syndrome	1.22e-05	4.24e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—SULT2A1—polycystic ovary syndrome	1.22e-05	4.23e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CYP17A1—polycystic ovary syndrome	1.21e-05	4.22e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—SULT2A1—polycystic ovary syndrome	1.21e-05	4.2e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—YAP1—polycystic ovary syndrome	1.21e-05	4.19e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IGF1—polycystic ovary syndrome	1.21e-05	4.19e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—AKT2—polycystic ovary syndrome	1.21e-05	4.19e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—INS—polycystic ovary syndrome	1.19e-05	4.14e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—NAMPT—polycystic ovary syndrome	1.19e-05	4.13e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—SLC2A4—polycystic ovary syndrome	1.19e-05	4.13e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.19e-05	4.12e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.18e-05	4.1e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—RRM2—polycystic ovary syndrome	1.18e-05	4.1e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	1.18e-05	4.1e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CYP11A1—polycystic ovary syndrome	1.17e-05	4.08e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—MTHFR—polycystic ovary syndrome	1.17e-05	4.07e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—RRM2—polycystic ovary syndrome	1.17e-05	4.06e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NRG1—polycystic ovary syndrome	1.16e-05	4.05e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.16e-05	4.05e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—NAMPT—polycystic ovary syndrome	1.16e-05	4.03e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—TH—polycystic ovary syndrome	1.15e-05	4.01e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—AKT2—polycystic ovary syndrome	1.15e-05	4e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.15e-05	3.98e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CYP11A1—polycystic ovary syndrome	1.14e-05	3.98e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	1.14e-05	3.95e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—YAP1—polycystic ovary syndrome	1.13e-05	3.92e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—SLC2A4—polycystic ovary syndrome	1.12e-05	3.9e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CYP19A1—polycystic ovary syndrome	1.12e-05	3.88e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—AKR1C3—polycystic ovary syndrome	1.11e-05	3.85e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—IL6—polycystic ovary syndrome	1.1e-05	3.84e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—IL6—polycystic ovary syndrome	1.1e-05	3.81e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—SERPINE1—polycystic ovary syndrome	1.09e-05	3.8e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	1.09e-05	3.8e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CYP17A1—polycystic ovary syndrome	1.09e-05	3.79e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—BCL2—polycystic ovary syndrome	1.09e-05	3.79e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—NAMPT—polycystic ovary syndrome	1.08e-05	3.76e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—AKR1C3—polycystic ovary syndrome	1.08e-05	3.76e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	1.08e-05	3.75e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.08e-05	3.74e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CYP11A1—polycystic ovary syndrome	1.07e-05	3.72e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CYP17A1—polycystic ovary syndrome	1.06e-05	3.7e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.06e-05	3.69e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CYP19A1—polycystic ovary syndrome	1.05e-05	3.67e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—TH—polycystic ovary syndrome	1.05e-05	3.65e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	1.05e-05	3.65e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—SLC2A4—polycystic ovary syndrome	1.02e-05	3.55e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	1.02e-05	3.54e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IL6—polycystic ovary syndrome	1.01e-05	3.52e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—AKR1C3—polycystic ovary syndrome	1.01e-05	3.51e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	1e-05	3.49e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	1e-05	3.48e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IRS2—polycystic ovary syndrome	9.97e-06	3.47e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—GNAS—polycystic ovary syndrome	9.96e-06	3.46e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CYP17A1—polycystic ovary syndrome	9.94e-06	3.46e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—VEGFA—polycystic ovary syndrome	9.82e-06	3.41e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—LEP—polycystic ovary syndrome	9.76e-06	3.39e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—IL6—polycystic ovary syndrome	9.68e-06	3.36e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CYP19A1—polycystic ovary syndrome	9.61e-06	3.34e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PPARG—polycystic ovary syndrome	9.49e-06	3.3e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—NCOR1—polycystic ovary syndrome	9.49e-06	3.3e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—VEGFA—polycystic ovary syndrome	9.46e-06	3.29e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—TH—polycystic ovary syndrome	9.43e-06	3.28e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—GNAS—polycystic ovary syndrome	9.41e-06	3.27e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—POMC—polycystic ovary syndrome	9.36e-06	3.25e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—IL6—polycystic ovary syndrome	9.35e-06	3.25e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—INS—polycystic ovary syndrome	9.31e-06	3.24e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—TH—polycystic ovary syndrome	9.21e-06	3.2e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—SLC2A4—polycystic ovary syndrome	9.18e-06	3.19e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	9.14e-06	3.18e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CYP1A1—polycystic ovary syndrome	9e-06	3.13e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—NCOR1—polycystic ovary syndrome	8.97e-06	3.12e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	8.96e-06	3.11e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—VEGFA—polycystic ovary syndrome	8.95e-06	3.11e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	8.93e-06	3.11e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IRS1—polycystic ovary syndrome	8.71e-06	3.03e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—TH—polycystic ovary syndrome	8.68e-06	3.02e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	8.65e-06	3.01e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CYP19A1—polycystic ovary syndrome	8.63e-06	3e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—TH—polycystic ovary syndrome	8.6e-06	2.99e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—IL6—polycystic ovary syndrome	8.59e-06	2.99e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GNAS—polycystic ovary syndrome	8.58e-06	2.98e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	8.44e-06	2.93e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL6—polycystic ovary syndrome	8.43e-06	2.93e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	8.42e-06	2.93e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—MTHFR—polycystic ovary syndrome	8.39e-06	2.92e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—POMC—polycystic ovary syndrome	8.38e-06	2.91e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—SLC2A4—polycystic ovary syndrome	8.37e-06	2.91e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—INS—polycystic ovary syndrome	8.34e-06	2.9e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—NCOR1—polycystic ovary syndrome	8.17e-06	2.84e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IGF1—polycystic ovary syndrome	8.07e-06	2.8e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—AKT2—polycystic ovary syndrome	8.06e-06	2.8e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	7.96e-06	2.77e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	7.94e-06	2.76e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—MTHFR—polycystic ovary syndrome	7.92e-06	2.75e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—VEGFA—polycystic ovary syndrome	7.88e-06	2.74e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CYP19A1—polycystic ovary syndrome	7.87e-06	2.74e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CYP1A1—polycystic ovary syndrome	7.75e-06	2.69e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	7.71e-06	2.68e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GNAS—polycystic ovary syndrome	7.7e-06	2.68e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SERPINE1—polycystic ovary syndrome	7.66e-06	2.66e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	7.52e-06	2.61e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	7.43e-06	2.58e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—NCOR1—polycystic ovary syndrome	7.34e-06	2.55e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—MTHFR—polycystic ovary syndrome	7.22e-06	2.51e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	7.16e-06	2.49e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	7.14e-06	2.48e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	7.08e-06	2.46e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	7.05e-06	2.45e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GNAS—polycystic ovary syndrome	7.02e-06	2.44e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CYP1A1—polycystic ovary syndrome	6.95e-06	2.42e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PPARG—polycystic ovary syndrome	6.8e-06	2.36e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IL6—polycystic ovary syndrome	6.79e-06	2.36e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	6.79e-06	2.36e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	6.75e-06	2.35e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—POMC—polycystic ovary syndrome	6.71e-06	2.33e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—NCOR1—polycystic ovary syndrome	6.69e-06	2.33e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—INS—polycystic ovary syndrome	6.67e-06	2.32e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	6.66e-06	2.32e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	6.56e-06	2.28e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IL6—polycystic ovary syndrome	6.54e-06	2.28e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—MTHFR—polycystic ovary syndrome	6.48e-06	2.25e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PPARG—polycystic ovary syndrome	6.42e-06	2.23e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	6.4e-06	2.22e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CYP1A1—polycystic ovary syndrome	6.34e-06	2.2e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—POMC—polycystic ovary syndrome	6.34e-06	2.2e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	6.33e-06	2.2e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—INS—polycystic ovary syndrome	6.3e-06	2.19e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—IL6—polycystic ovary syndrome	6.17e-06	2.14e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	5.96e-06	2.07e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—MTHFR—polycystic ovary syndrome	5.91e-06	2.06e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PPARG—polycystic ovary syndrome	5.86e-06	2.04e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—POMC—polycystic ovary syndrome	5.78e-06	2.01e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—INS—polycystic ovary syndrome	5.74e-06	2e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—TH—polycystic ovary syndrome	5.67e-06	1.97e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL6—polycystic ovary syndrome	5.64e-06	1.96e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	5.52e-06	1.92e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL6—polycystic ovary syndrome	5.45e-06	1.89e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—VEGFA—polycystic ovary syndrome	5.27e-06	1.83e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PPARG—polycystic ovary syndrome	5.26e-06	1.83e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—IL6—polycystic ovary syndrome	5.2e-06	1.81e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	5.19e-06	1.8e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—POMC—polycystic ovary syndrome	5.19e-06	1.8e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—INS—polycystic ovary syndrome	5.16e-06	1.79e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	5.13e-06	1.78e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—POMC—polycystic ovary syndrome	5.06e-06	1.76e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—INS—polycystic ovary syndrome	5.03e-06	1.75e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	4.84e-06	1.68e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PPARG—polycystic ovary syndrome	4.79e-06	1.67e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	4.77e-06	1.66e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—INS—polycystic ovary syndrome	4.74e-06	1.65e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—POMC—polycystic ovary syndrome	4.73e-06	1.64e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—INS—polycystic ovary syndrome	4.7e-06	1.63e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	4.63e-06	1.61e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	4.41e-06	1.53e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	4.18e-06	1.45e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	3.9e-06	1.36e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL6—polycystic ovary syndrome	3.64e-06	1.27e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	3.16e-06	1.1e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	3.12e-06	1.08e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—INS—polycystic ovary syndrome	3.1e-06	1.08e-05	CbGpPWpGaD
